Search | Clinical Trials Finder

Conditions: Colorectal Cancer, Neoplasms, Colorectal
Interventions: CS7017, irinotecan, leucovorin, and 5-fluorouracil (5-FU) (FOLFIRI); Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 6
States / cities: Beverly Hills, California • Fullerton, California • Washington D.C., District of Columbia + 3 more

Conditions: Pain, Postoperative
Interventions: Cold therapy via reusable cold gel pack; Device
Lead sponsor: Cleveland Clinic Florida; Other
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Weston, Florida

Conditions: HIV Infections
Interventions: Cemiplimab, Placebo; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 64 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 3
States / cities: Birmingham, Alabama • San Diego, California • Chapel Hill, North Carolina

Conditions: Alzheimer's Disease
Interventions: Lecanemab 2.5 mg/kg, Lecanemab 5.0 mg/kg, Lecanemab 10 mg/kg, Placebo; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 50 Years to 90 Years
Enrollment: 856 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2024
U.S. locations: 91
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 70 more

Conditions: Dental Plaque Accumulation
Interventions: MIIP-E2 containing gum, placebo gum without MIIP-E2; Device
Lead sponsor: Lactea Therapeutics, LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Chemotherapeutic Agent Toxicity, Neuropathy, Neurotoxicity Syndrome, Pain, Stage IIIA Fallopian Tube Cancer, Stage IIIA Ovarian Cancer, Stage IIIA Primary Peritoneal Cancer, Stage IIIB Fallopian Tube Cancer, Stage IIIB Ovarian Cancer, Stage IIIB Primary Peritoneal Cancer, Stage IIIC Fallopian Tube Cancer, Stage IIIC Ovarian Cancer, Stage IIIC Primary Peritoneal Cancer, Stage IV Fallopian Tube Cancer, Stage IV Ovarian Cancer, Stage IV Primary Peritoneal Cancer
Interventions: Carboplatin, Glutathione, Laboratory Biomarker Analysis, Paclitaxel, Placebo, Quality-of-Life Assessment; Drug · Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 195 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 390
States / cities: Mobile, Alabama • Fairbanks, Alaska • Scottsdale, Arizona + 259 more

Conditions: HIV Seropositivity
Interventions: Placebo, Rouvastatin calcium; Drug
Lead sponsor: Alison Morris; Other
Eligibility: 18 Years to 80 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 3
States / cities: Los Angeles, California • San Francisco, California • Pittsburgh, Pennsylvania

Conditions: Melanoma
Interventions: IFNα2b, PEG- IFNα2b; Drug
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2017
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Rhinitis, Allergic, Seasonal
Interventions: Amb a 1 immunostimulatory oligodeoxyribonucleotide conjugate, Histamine base; Biological
Lead sponsor: Dynavax Technologies Corporation; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 738 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 28
States / cities: Oxford, Alabama • Stockbridge, Georgia • Normal, Illinois + 22 more

Conditions: Hematopoietic Stem Cell Transplant, Pediatric Cancer, Deconditioning
Interventions: Exercise regimen; Behavioral
Lead sponsor: Phoenix Children's Hospital; Other
Eligibility: 4 Years to 21 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Suicide, Depression, Family Relationships
Interventions: Attachment-Based Family Therapy, Family-Enhanced Non-directive Supportive Therapy; Behavioral
Lead sponsor: Drexel University; Other
Eligibility: 12 Years to 18 Years
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Healthy
Interventions: Placebo, RSV preF Protein 50 mcg, RSV preF Protein 150 mcg, Ad26.RSV.preF 1*10^11 vp, Mixture of Ad26.RSV.preF 5*10^10 vp Plus RSV preF Protein 50 mcg, Mixture of Ad26.RSV.preF 5*10^10 vp Plus RSV preF Protein 150 mcg, Mixture of Ad26.RSV.preF 1*10^11 vp Plus RSV preF Protein 50 mcg, Mixture of Ad26.RSV.preF 1*10^11 vp Plus RSV preF Protein 150 mcg, Selected Regimen; Biological
Lead sponsor: Janssen Vaccines & Prevention B.V.; Industry
Eligibility: 60 Years and older
Enrollment: 669 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2022
U.S. locations: 6
States / cities: Huntsville, Alabama • San Diego, California • Melbourne, Florida + 3 more

Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: repaglinide and metformin combination tablet, rosiglitazone and metformin combination tablet; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 560 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 102
States / cities: Vestavia Hills, Alabama • Glendale, Arizona • Mesa, Arizona + 90 more

Conditions: Hepatitis C
Interventions: Use of Tappt App; Other
Lead sponsor: University of Illinois at Chicago; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Eosinophilic Esophagitis (EoE)
Interventions: Dupilumab, Matching Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 1 Year to 11 Years
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 26
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 18 more

Conditions: Obesity, Uric Acid Stones, Type 2 Diabetes Mellitus in Obese, Pre-Diabetes
Interventions: Phentermine / Topiramate Oral Product, Citrate Salts, Allopurinol, Diet; Drug · Combination Product
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 75 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Cystic Fibrosis-related Diabetes
Interventions: Bionic Pancreas, Usual Care; Device · Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 10 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Down Syndrome, Intellectual Disability
Interventions: Memantine, Placebo; Drug
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 15 Years to 32 Years
Enrollment: 160 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2020
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Hidradenitis Suppurativa (HS)
Interventions: ORKA-002, Placebo; Drug · Other
Lead sponsor: Oruka Therapeutics, Inc.; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 15
States / cities: Birmingham, Alabama • Fountain Valley, California • Los Angeles, California + 12 more

Conditions: Myofacial Pain, Pain, Neck, Pain, Back, Cervical Fusion
Interventions: Trigger point injection with bupivacaine, Trigger point injection with normal saline, Lidocaine skin wheal; Drug
Lead sponsor: George Washington University; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Atopic Dermatitis
Interventions: Tralokinumab, Placebo; Drug
Lead sponsor: LEO Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 794 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 40
States / cities: Hot Springs, Arkansas • Encinitas, California • Fullerton, California + 35 more

Conditions: Malignant Glioma
Interventions: Nuvigil®, Placebo; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Stroke Rehabilitation, Stroke, Neurorecovery
Interventions: Arm Basis Training; Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Suicide, Attempted
Interventions: Ketamine Hydrochloride, Saline, CAMS Therapy; Drug · Behavioral
Lead sponsor: Tatiana Falcone, MD; Other
Eligibility: 14 Years to 30 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Cleveland, Ohio

Search by objective public record fields.

Study of CS-7017 in Combination With FOLFIRI in Subjects With Metastatic Colorectal Cancer Who Failed First-Line Therapy

Effect of Cold Therapy Implementation on Multi-modal Postoperative Pain Management

Safety and Immunotherapeutic Activity of an Anti-PD-1 Antibody (Cemiplimab) in Participants With HIV-1 on Suppressive cART

A Study to Evaluate Safety, Tolerability, and Efficacy of Lecanemab in Subjects With Early Alzheimer's Disease

4-day Plaque Accumulation Model Evaluating Compound Containing Gum

Glutathione in Preventing Peripheral Neuropathy Caused by Paclitaxel and Carboplatin in Patients With Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer

Statins for Pulmonary and Cardiac Complications of Chronic HIV - Coordinating Center

Pilot Study of IFN α2b for Melanoma Patients

Efficacy and Safety Study of TOLAMBA™ in Ragweed-Allergic Adults

Benefits of Intrahospital Exercise Program in Pediatric HSCT

Attachment Based Family Therapy for Suicidal Adolescents

A Study to Evaluate the Safety and Immunogenicity for Regimen Selection of Ad26.RSV.preF and/or RSV preF Protein Combinations Followed by Expanded Safety Evaluation in Adults Aged 60 Years and Older

Effect of Repaglinide and Metformin Combination Tablet or Rosiglitazone and Metformin in Fixed Dose Combination on Blood Glucose Control in Patients With Type 2 Diabetes

HCV Tappt Adherence Study

Study to Investigate the Efficacy and Safety of Dupilumab in Pediatric Patients With Active Eosinophilic Esophagitis (EoE)

Phentermine/Topiramate for Uric Acid Stones

Feasibility of Outpatient Closed Loop Control With the iLet Bionic Pancreas in Cystic Fibrosis Related Diabetes

Down Syndrome Memantine Follow-up Study

ORKA-002 Versus Placebo in Participants With Moderate-to-Severe Hidradenitis Suppurativa

Trigger Point Injections in Anterior Cervical Surgery

Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 2 (ECZema TRAlokinumab Trial no. 2)

Nuvigil or Placebo in Newly Diagnosed Malignant Glioma

Substrates for Post-Stroke Arm Rehabilitation

Ketamine Treatment of Youth Suicide Attempters